Protocol Ledger

NCT04775485 · Phase II · RECRUITING

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Interventional Phase II clinical trial protocol NCT04775485 sponsored by Day One Biopharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-22 Enrollment: 141 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04775485
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)141 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04775485
Protocol FieldVerified Registry Value
NCT IdentifierNCT04775485
Consolidated Lead SponsorDay One Biopharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment141 participants (ESTIMATED)
Registered Start Date2021-04-22
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI